ClinicalTrials.gg
RecruitingNCT06780722HEPHAISTOSUpdated Jun 25, 2026

Study of the Occurrence of Cardiocirculatory Arrest as a Function of the Level of Hypoxemia During a Maastricht 3 Procedure

An observational study in Cardiac Arrest and Reanimation, sponsored by Nantes University Hospital. Recruiting at 12 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.

Planned enrollment
37th of 47
50 · median 150
Started
2025
with 9 others
Observational
47 of 106
17 open now
Primary completion
2027-06
later than 14 of 32 live
Registered
92nd of 106
by date
Lead sponsor
5 of 106
Nantes University Hospital

Among the 106 studies in Heart Arrest with a site in France, this one is the 37th largest by planned enrollment of the 47 observational ones that give a count, is one of 10 that started in 2025, is one of 47 observational ones, reaches primary completion later than 14 of the 32 other live ones, and was the 92nd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Heart Arrest with a site in France, or all of them as a file.
02

Study summary

Evaluation of the level of hypoxemia during the occurrence of cardiocirculatory arrest during a Maastricht III organ donation procedure.

Read the detailed description

Evaluation of the level of hypoxemia during the occurrence of cardiocirculatory arrest during a Maastricht III organ donation procedure.

03

Conditions studied

  • Cardiac Arrest
  • Reanimation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who may be candidates for an organ donation procedure in the event of death in intensive care following the implementation of a procedure to discontinue active therapies.

Eligibility criteria

FOR THE DONORS :

Inclusion Criteria :

  • Patient over 18 years of age
  • Organ donation procedure initiated in accordance with the legislation and procedures in force in France for the Maastricht III category
  • No opposition formulated by the relative to the patient's participation in the study

Exclusion Criteria :

  • Patient registered on the national register of refusals or living refusal of donation
  • Pregnant or breast-feeding women
  • Patients under guardianship, curatorship or legal protection
  • Medical to organ donation according to the recommendations of the Agence de Biomédecine currently in force in France

FOR THE RECEIVER

Inclusion Criteria :

  • No opposition to the collection of data concerning him/her
  • Patient over 18 at pre-transplant consultation
  • Patient who has received an organ from a donor participating in the HEPHAISTOS protocol

Exclusion Criteria :

- Patients under guardianship, curatorship or legal protection

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • Otherblood sampling

    * The first sample is taken at the start of the therapeutic stop. * The second sample is taken when the mean arterial pressure drops to 45mmHg. * The third sample is taken when circulatory arrest occurs. * The fourth sample is taken at the start of extracorporeal circulation. These four samples will be destroyed at the end of the study.

06

What researchers measure

Primary outcomes

  1. PaO2 level

    PaO2 level and its 95% confidence interval in the event of circulatory cardiac arrest, defined as a pulse pressure below 5 mmHg, during a Maastricht III procedure.

    Time frame: 24 hours

Secondary outcomes

  1. Spo2 Level

    Define the level of Spo2 (and its 95% confidence interval) at the time of cardiocirculatory arrest during a Maastricht III procedure.

    Time frame: 24 hours

  2. Time between occurrence of first episode of pulsed oxygen saturation below 95% and onset of cardiocirculatory arrest

    Define the time (and its 95% confidence interval) between the occurrence of the first first episode of pulsed oxygen saturation below 95% and the onset of cardio-circulatory arrest defined by absence of pulsed pressure below 5 mmHg.

    Time frame: 24 hours

  3. Correlation between the rate of delayed recovery of renal function in the recipient and the presence of hypoxemia at the time of cardiocirculatory arrest in the donor.

    Delayed recovery of renal function will be confirmed if the recipient undergoes dialysis within the first 7 days after transplantation. Hypoxemia is defined as a PaO2 less than or equal to the median value.

    Time frame: 7 days

07

Study locations

11 of 12 sites recruiting
  • CHU ANGERS - Réanimation médicale
    Angers, France
    Recruiting
  • CH ANNECY GENEVOIS - Réanimation médicale - Coordination Prélèvements multi-organes
    Annecy, France
    Recruiting
  • CH AVIGNON - CH Henri Duffaut - Réanimation polyvalente
    Avignon, France
    Recruiting
  • CHD Vendée - Les Oudairies - Médecine Intensive Réanimation
    La Roche-sur-Yon, France
    Recruiting
  • CHU LILLE - Hôpital Roger Salengro - Médecine Intensive Réanimation
    Lille, France
    Recruiting
  • CHU de Nantes - Hôpital Laennec
    Nantes, France
    Recruiting
  • CHU NANTES +- Médecine Intensive Réanimation
    Nantes, France
    Recruiting
  • CHRU ORLEANS -Médecine Intensive Réanimation - Coordination Prélèvements multi-organes
    Orléans, France
    Recruiting
  • CHU POITIERS - Anesthésie Réanimation - Coordination Prélèvements multi-organes
    Poitiers, France
    Not yet recruiting
  • CHU RENNES - CHU Pontchaillou - Réanimation médicale
    Rennes, France
    Recruiting
  • CHRU TOURS - Hôpital Bretonneau - Médecine Intensive Réanimation
    Tours, France
    Recruiting
  • CHBA Vannes-Auray - Réanimation Polyvalente
    Vannes, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 17 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Jun 6, 2027
CompletionEst.
Jun 19, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780722
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Dec 19, 2025
Primary completion
Jun 6, 2027 (estimated)
Completion
Jun 19, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Jean Baptiste LASCARROU
Contact
Jeanbaptiste.lascarrou@chu-nantes.fr
02 40 08 73 76 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion